Category: 2021

October | 2021

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 21, 2021 Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer re

October | 2021

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 19, 2021 Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer relat

October | 2021

CEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga’s Cannabis Capital Conference

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 14, 2021 Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer relat

September | 2021

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

TEL AVIV, Israel and BETHESDA, Maryland, Sep. 30, 2021 a global leader in the development of cancer related cannabinoid-based medicine and a pioneer

September | 2021

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

TEL AVIV, Israel and BETHESDA, Maryland, Sep 22, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

September | 2021

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, Sep 21, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

September | 2021

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

TEL AVIV, Israel and BETHESDA, Maryland, Sep 13, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX),a global leader in the development of cancer relat

August | 2021

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals’ Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug 23, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX),a global leader in the development of cancer relat

August | 2021

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals’ Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug 04, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

July | 2021

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, Jul 20, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

July | 2021

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, Jun 28, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

June | 2021

Cannabics Pharmaceuticals’ Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

TEL AVIV, Israel and BETHESDA, Maryland, Jun 28, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

June | 2021

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, Jun 17, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

June | 2021

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program

TEL AVIV, Israel and BETHESDA, Maryland, Jun 03, 2021 The announcement comes following the launching of a Melanoma research program in April 2021, an

May | 2021

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company’s Personalized Medicine Drug Discovery Technology

TEL AVIV, Israel and BETHESDA, Maryland, May 25, 2021 Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related can

May | 2021

Cannabics Pharmaceuticals Receives Patent “Notice of Allowance” From The Mexican Patent and Trademark Office (IMPI)

TEL AVIV, Israel and BETHESDA, Maryland, May 11, 2021 Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related can

May | 2021

Cannabics Pharmaceuticals Receives Patent “Notice of Allowance” From The Mexican Patent and Trademark Office (IMPI)

TEL AVIV, Israel and BETHESDA, Maryland, May 6, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer relat

April | 2021

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track

TEL AVIV, Israel and BETHESDA, Maryland, April 26, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of

April | 2021

Cannabics Pharmaceuticals’ Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

TEL AVIV, Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the develo

March | 2021

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

TEL AVIV, Israel and BETHESDA, Md., March 31, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the devel

March | 2021

Cannabics Pharmaceuticals’ Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

TEL AVIV, Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the develo

February | 2021

Cannabics Pharmaceuticals’ in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 17, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of

February | 2021

Cannabics Pharmaceuticals’ in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company’s Proprietary Drug Candidate for Colorectal Cancer

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the de

February | 2021

Cannabics Pharmaceutical’s Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company’s Proprietary Drug Candidate for Colorectal Cancer

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 3, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB:CNBX ), a global leader in the develop